Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
NCT05848843 · M.D. Anderson Cancer Center · PHASE1 · withdrawn · last registry update 2024-01-23 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “0 participant accrual” | Open Targets' class: insufficient enrollment | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-13Phase 3 first posted: National Cancer Institute (NCI), Ceralasertib + Durvalumab (NCT06732401)
- 2024-12-02Phase 3 first posted: BioNTech SE, Pumitamig + Atezolizumab (NCT06712355)
- 2024-10-17Phase 3 first posted: Bristol-Myers Squibb, BMS-986489 (Atigotatug+Nivolumab) + Atezolizumab (NCT06646276)
- 2024-10-09Phase 3 first posted: Alliance for Clinical Trials in Oncology, Cisplatin + Carboplatin (NCT06632327)
- 2024-07-12Phase 3 first posted: National Cancer Institute (NCI), Durvalumab (NCT06498635)
- 2024-02-28Phase 3 first posted: ETOP IBCSG Partners Foundation, Adjuvant durvalumab (NCT06284317)
- 2024-01-18Phase 3 first posted: Amgen, Tarlatamab + Durvalumab (NCT06211036)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision